Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B
Aim Risk prediction models for hepatocellular carcinoma (HCC) development are available. However, the influence of antiviral therapy (AVT) on these models in patients with chronic hepatitis B is unknown. Methods The dynamic changes in risk prediction models during AVT and the association between ris...
Gespeichert in:
| Veröffentlicht in: | Hepatology research 2021-04, Vol.51 (4), p.406-416 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 416 |
|---|---|
| container_issue | 4 |
| container_start_page | 406 |
| container_title | Hepatology research |
| container_volume | 51 |
| creator | Chon, Hye Yeon Lee, Jae Seung Lee, Hye Won Chun, Ho Soo Kim, Beom Kyung Park, Jun Yong Kim, Do Young Ahn, Sang Hoon Kim, Seung Up |
| description | Aim
Risk prediction models for hepatocellular carcinoma (HCC) development are available. However, the influence of antiviral therapy (AVT) on these models in patients with chronic hepatitis B is unknown.
Methods
The dynamic changes in risk prediction models during AVT and the association between risk prediction model and the risk of chronic hepatitis B‐related HCC development were investigated. Between 2005 and 2017, 4917 patients with chronic hepatitis B (3361 noncirrhotic, 1556 cirrhotic) were recruited.
Results
The mean age of the study population was 49.3 years and 60.6% (n = 2980) of the patients were male. The mean Chinese University‐HCC (CU‐HCC) score was 12.7 at baseline in the overall study population, and decreased significantly (mean, 8.7) after 1 year of AVT (p 0.05). The proportion of high‐risk patients (CU‐HCC score ≥ 20) was 28.9% at baseline, and decreased significantly after 1 year of AVT (5.0%; p 0.05). In addition to the score at baseline, the CU‐HCC score at 1 year of AVT independently predicted the risk of HCC development (hazard ratio = 1.072; p |
| doi_str_mv | 10.1111/hepr.13600 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2465441236</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2465441236</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3810-47032c94814cefc41c4b8b32b9356eb5ec3e12e415ff17409bf458a4055e8eae3</originalsourceid><addsrcrecordid>eNp9kU1LxDAQhoMofqxe_AES8CJCNZ_d7lHFLxAUUfAW0uyUjbZNTdKVvfrLzdrVgwfnMjPwzDvDvAjtU3JCU5zOoPMnlOeErKFtWoxZRrh4WU81L_Is5yLfQjshvBJCx4SJTbTFOROM53Ibfd42nTYRuwrrNtq59brGcQZedwvsWuxteMOdh6k10aa-cVOoceU8Tlt1dAbquq-1x0Z7Y1vXaDyFOdSua6CN2LY4UTaVAX_YOMNm5l1rzTBtow34fBdtVLoOsLfKI_R8dfl0cZPd3V_fXpzdZYYXlGRiTDgzE1FQYaAyghpRFiVn5YTLHEoJhgNlIKisKjoWZFJWQhZaECmhAA18hI4G3c679x5CVI0Ny_t1C64PiolcCkHTXxJ6-Ad9db1v03WKSTJhjFNJE3U8UMa7EDxUqvO20X6hKFFLZ9TSGfXtTIIPVpJ92cD0F_2xIgF0AD5sDYt_pNTN5cPjIPoFdBSakg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2509223151</pqid></control><display><type>article</type><title>Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B</title><source>Access via Wiley Online Library</source><creator>Chon, Hye Yeon ; Lee, Jae Seung ; Lee, Hye Won ; Chun, Ho Soo ; Kim, Beom Kyung ; Park, Jun Yong ; Kim, Do Young ; Ahn, Sang Hoon ; Kim, Seung Up</creator><creatorcontrib>Chon, Hye Yeon ; Lee, Jae Seung ; Lee, Hye Won ; Chun, Ho Soo ; Kim, Beom Kyung ; Park, Jun Yong ; Kim, Do Young ; Ahn, Sang Hoon ; Kim, Seung Up</creatorcontrib><description>Aim
Risk prediction models for hepatocellular carcinoma (HCC) development are available. However, the influence of antiviral therapy (AVT) on these models in patients with chronic hepatitis B is unknown.
Methods
The dynamic changes in risk prediction models during AVT and the association between risk prediction model and the risk of chronic hepatitis B‐related HCC development were investigated. Between 2005 and 2017, 4917 patients with chronic hepatitis B (3361 noncirrhotic, 1556 cirrhotic) were recruited.
Results
The mean age of the study population was 49.3 years and 60.6% (n = 2980) of the patients were male. The mean Chinese University‐HCC (CU‐HCC) score was 12.7 at baseline in the overall study population, and decreased significantly (mean, 8.7) after 1 year of AVT (p < 0.001). The score was maintained throughout 5 years of AVT (mean, 8.4–8.8; p > 0.05). The proportion of high‐risk patients (CU‐HCC score ≥ 20) was 28.9% at baseline, and decreased significantly after 1 year of AVT (5.0%; p < 0.001), and remained stable through 5 years of AVT (2.2%–3.6%; p > 0.05). In addition to the score at baseline, the CU‐HCC score at 1 year of AVT independently predicted the risk of HCC development (hazard ratio = 1.072; p < 0.001), together with male gender and platelet count (all p < 0.05).
Conclusions
The CU‐HCC score significantly decreased at 1 year of AVT and was maintained thereafter. The CU‐HCC score after 1 year of AVT independently predicted the risk of HCC development in patients with chronic hepatitis B.</description><identifier>ISSN: 1386-6346</identifier><identifier>EISSN: 1872-034X</identifier><identifier>DOI: 10.1111/hepr.13600</identifier><identifier>PMID: 33242365</identifier><language>eng</language><publisher>Netherlands: Wiley Subscription Services, Inc</publisher><subject>Antiviral agents ; antiviraltherapy ; chronic hepatitis B ; Hepatitis B ; Hepatocellular carcinoma ; Interferon ; Liver cancer ; Population studies ; Prediction models ; risk prediction model</subject><ispartof>Hepatology research, 2021-04, Vol.51 (4), p.406-416</ispartof><rights>2020 The Japan Society of Hepatology</rights><rights>2020 The Japan Society of Hepatology.</rights><rights>2021 The Japan Society of Hepatology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3810-47032c94814cefc41c4b8b32b9356eb5ec3e12e415ff17409bf458a4055e8eae3</citedby><cites>FETCH-LOGICAL-c3810-47032c94814cefc41c4b8b32b9356eb5ec3e12e415ff17409bf458a4055e8eae3</cites><orcidid>0000-0002-8327-3439 ; 0000-0001-6324-2224 ; 0000-0002-3629-4624 ; 0000-0002-3552-3560 ; 0000-0003-4009-8180 ; 0000-0002-2371-0967 ; 0000-0002-7066-6612 ; 0000-0002-5363-2496 ; 0000-0002-9658-8050</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhepr.13600$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhepr.13600$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33242365$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chon, Hye Yeon</creatorcontrib><creatorcontrib>Lee, Jae Seung</creatorcontrib><creatorcontrib>Lee, Hye Won</creatorcontrib><creatorcontrib>Chun, Ho Soo</creatorcontrib><creatorcontrib>Kim, Beom Kyung</creatorcontrib><creatorcontrib>Park, Jun Yong</creatorcontrib><creatorcontrib>Kim, Do Young</creatorcontrib><creatorcontrib>Ahn, Sang Hoon</creatorcontrib><creatorcontrib>Kim, Seung Up</creatorcontrib><title>Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B</title><title>Hepatology research</title><addtitle>Hepatol Res</addtitle><description>Aim
Risk prediction models for hepatocellular carcinoma (HCC) development are available. However, the influence of antiviral therapy (AVT) on these models in patients with chronic hepatitis B is unknown.
Methods
The dynamic changes in risk prediction models during AVT and the association between risk prediction model and the risk of chronic hepatitis B‐related HCC development were investigated. Between 2005 and 2017, 4917 patients with chronic hepatitis B (3361 noncirrhotic, 1556 cirrhotic) were recruited.
Results
The mean age of the study population was 49.3 years and 60.6% (n = 2980) of the patients were male. The mean Chinese University‐HCC (CU‐HCC) score was 12.7 at baseline in the overall study population, and decreased significantly (mean, 8.7) after 1 year of AVT (p < 0.001). The score was maintained throughout 5 years of AVT (mean, 8.4–8.8; p > 0.05). The proportion of high‐risk patients (CU‐HCC score ≥ 20) was 28.9% at baseline, and decreased significantly after 1 year of AVT (5.0%; p < 0.001), and remained stable through 5 years of AVT (2.2%–3.6%; p > 0.05). In addition to the score at baseline, the CU‐HCC score at 1 year of AVT independently predicted the risk of HCC development (hazard ratio = 1.072; p < 0.001), together with male gender and platelet count (all p < 0.05).
Conclusions
The CU‐HCC score significantly decreased at 1 year of AVT and was maintained thereafter. The CU‐HCC score after 1 year of AVT independently predicted the risk of HCC development in patients with chronic hepatitis B.</description><subject>Antiviral agents</subject><subject>antiviraltherapy</subject><subject>chronic hepatitis B</subject><subject>Hepatitis B</subject><subject>Hepatocellular carcinoma</subject><subject>Interferon</subject><subject>Liver cancer</subject><subject>Population studies</subject><subject>Prediction models</subject><subject>risk prediction model</subject><issn>1386-6346</issn><issn>1872-034X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kU1LxDAQhoMofqxe_AES8CJCNZ_d7lHFLxAUUfAW0uyUjbZNTdKVvfrLzdrVgwfnMjPwzDvDvAjtU3JCU5zOoPMnlOeErKFtWoxZRrh4WU81L_Is5yLfQjshvBJCx4SJTbTFOROM53Ibfd42nTYRuwrrNtq59brGcQZedwvsWuxteMOdh6k10aa-cVOoceU8Tlt1dAbquq-1x0Z7Y1vXaDyFOdSua6CN2LY4UTaVAX_YOMNm5l1rzTBtow34fBdtVLoOsLfKI_R8dfl0cZPd3V_fXpzdZYYXlGRiTDgzE1FQYaAyghpRFiVn5YTLHEoJhgNlIKisKjoWZFJWQhZaECmhAA18hI4G3c679x5CVI0Ny_t1C64PiolcCkHTXxJ6-Ad9db1v03WKSTJhjFNJE3U8UMa7EDxUqvO20X6hKFFLZ9TSGfXtTIIPVpJ92cD0F_2xIgF0AD5sDYt_pNTN5cPjIPoFdBSakg</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Chon, Hye Yeon</creator><creator>Lee, Jae Seung</creator><creator>Lee, Hye Won</creator><creator>Chun, Ho Soo</creator><creator>Kim, Beom Kyung</creator><creator>Park, Jun Yong</creator><creator>Kim, Do Young</creator><creator>Ahn, Sang Hoon</creator><creator>Kim, Seung Up</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8327-3439</orcidid><orcidid>https://orcid.org/0000-0001-6324-2224</orcidid><orcidid>https://orcid.org/0000-0002-3629-4624</orcidid><orcidid>https://orcid.org/0000-0002-3552-3560</orcidid><orcidid>https://orcid.org/0000-0003-4009-8180</orcidid><orcidid>https://orcid.org/0000-0002-2371-0967</orcidid><orcidid>https://orcid.org/0000-0002-7066-6612</orcidid><orcidid>https://orcid.org/0000-0002-5363-2496</orcidid><orcidid>https://orcid.org/0000-0002-9658-8050</orcidid></search><sort><creationdate>202104</creationdate><title>Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B</title><author>Chon, Hye Yeon ; Lee, Jae Seung ; Lee, Hye Won ; Chun, Ho Soo ; Kim, Beom Kyung ; Park, Jun Yong ; Kim, Do Young ; Ahn, Sang Hoon ; Kim, Seung Up</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3810-47032c94814cefc41c4b8b32b9356eb5ec3e12e415ff17409bf458a4055e8eae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antiviral agents</topic><topic>antiviraltherapy</topic><topic>chronic hepatitis B</topic><topic>Hepatitis B</topic><topic>Hepatocellular carcinoma</topic><topic>Interferon</topic><topic>Liver cancer</topic><topic>Population studies</topic><topic>Prediction models</topic><topic>risk prediction model</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chon, Hye Yeon</creatorcontrib><creatorcontrib>Lee, Jae Seung</creatorcontrib><creatorcontrib>Lee, Hye Won</creatorcontrib><creatorcontrib>Chun, Ho Soo</creatorcontrib><creatorcontrib>Kim, Beom Kyung</creatorcontrib><creatorcontrib>Park, Jun Yong</creatorcontrib><creatorcontrib>Kim, Do Young</creatorcontrib><creatorcontrib>Ahn, Sang Hoon</creatorcontrib><creatorcontrib>Kim, Seung Up</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chon, Hye Yeon</au><au>Lee, Jae Seung</au><au>Lee, Hye Won</au><au>Chun, Ho Soo</au><au>Kim, Beom Kyung</au><au>Park, Jun Yong</au><au>Kim, Do Young</au><au>Ahn, Sang Hoon</au><au>Kim, Seung Up</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B</atitle><jtitle>Hepatology research</jtitle><addtitle>Hepatol Res</addtitle><date>2021-04</date><risdate>2021</risdate><volume>51</volume><issue>4</issue><spage>406</spage><epage>416</epage><pages>406-416</pages><issn>1386-6346</issn><eissn>1872-034X</eissn><abstract>Aim
Risk prediction models for hepatocellular carcinoma (HCC) development are available. However, the influence of antiviral therapy (AVT) on these models in patients with chronic hepatitis B is unknown.
Methods
The dynamic changes in risk prediction models during AVT and the association between risk prediction model and the risk of chronic hepatitis B‐related HCC development were investigated. Between 2005 and 2017, 4917 patients with chronic hepatitis B (3361 noncirrhotic, 1556 cirrhotic) were recruited.
Results
The mean age of the study population was 49.3 years and 60.6% (n = 2980) of the patients were male. The mean Chinese University‐HCC (CU‐HCC) score was 12.7 at baseline in the overall study population, and decreased significantly (mean, 8.7) after 1 year of AVT (p < 0.001). The score was maintained throughout 5 years of AVT (mean, 8.4–8.8; p > 0.05). The proportion of high‐risk patients (CU‐HCC score ≥ 20) was 28.9% at baseline, and decreased significantly after 1 year of AVT (5.0%; p < 0.001), and remained stable through 5 years of AVT (2.2%–3.6%; p > 0.05). In addition to the score at baseline, the CU‐HCC score at 1 year of AVT independently predicted the risk of HCC development (hazard ratio = 1.072; p < 0.001), together with male gender and platelet count (all p < 0.05).
Conclusions
The CU‐HCC score significantly decreased at 1 year of AVT and was maintained thereafter. The CU‐HCC score after 1 year of AVT independently predicted the risk of HCC development in patients with chronic hepatitis B.</abstract><cop>Netherlands</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33242365</pmid><doi>10.1111/hepr.13600</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-8327-3439</orcidid><orcidid>https://orcid.org/0000-0001-6324-2224</orcidid><orcidid>https://orcid.org/0000-0002-3629-4624</orcidid><orcidid>https://orcid.org/0000-0002-3552-3560</orcidid><orcidid>https://orcid.org/0000-0003-4009-8180</orcidid><orcidid>https://orcid.org/0000-0002-2371-0967</orcidid><orcidid>https://orcid.org/0000-0002-7066-6612</orcidid><orcidid>https://orcid.org/0000-0002-5363-2496</orcidid><orcidid>https://orcid.org/0000-0002-9658-8050</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6346 |
| ispartof | Hepatology research, 2021-04, Vol.51 (4), p.406-416 |
| issn | 1386-6346 1872-034X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2465441236 |
| source | Access via Wiley Online Library |
| subjects | Antiviral agents antiviraltherapy chronic hepatitis B Hepatitis B Hepatocellular carcinoma Interferon Liver cancer Population studies Prediction models risk prediction model |
| title | Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T15%3A54%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20antiviral%20therapy%20on%20risk%20prediction%20model%20for%20hepatocellular%20carcinoma%20development%20in%20patients%20with%20chronic%20hepatitis%20B&rft.jtitle=Hepatology%20research&rft.au=Chon,%20Hye%20Yeon&rft.date=2021-04&rft.volume=51&rft.issue=4&rft.spage=406&rft.epage=416&rft.pages=406-416&rft.issn=1386-6346&rft.eissn=1872-034X&rft_id=info:doi/10.1111/hepr.13600&rft_dat=%3Cproquest_cross%3E2465441236%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2509223151&rft_id=info:pmid/33242365&rfr_iscdi=true |